Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Common Stock Issued
Cash raised by issuing new shares.
Ocugen, Inc.NASDAQ: OCGN
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued turns positive
Q1 FY2026 common stock issued was $36.68M, compared with -$1M a year earlier. Trailing-twelve-month common stock issued was $56M. Over 3 fiscal years it compounded at -32.5% a year.
Context
- Common stock issued amounted to 415.3% of revenue in FY2025, down 535.5 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near $36.68M or moves back toward the trailing-twelve-month quarterly average of $14M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 18.33M USD
- Year-over-year change
- -52.5%
- 4-year CAGR
- -38.6%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.33M | -52.5% |
| FY2024 | 2024-12-31 | 38.56M | +85.3% |
| FY2023 | 2023-12-31 | 20.8M | -65.1% |
| FY2022 | 2022-12-31 | 59.57M | -53.9% |
| FY2021 | 2021-12-31 | 129.21M | — |
Common Stock Issued vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 common stock issued of $56M is the 6th largest of the 10 companies compared; the peer median is $59.25M.
- Its year-over-year change of +49.1% is the 6th highest of 9, against a peer median of +2511.1%.
- Common stock issued amounts to 1254.3% of revenue for OCGN, versus a peer median of 189.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M | +86.0% | — | 4878.8% |
| LTM Mar 2026 | $168.69M | +15305.3% | +27.8% | — | |
| LTM Mar 2026 | $143.13M | — | +19.7% | — | |
| LTM Mar 2026 | $96.67M | +98744.9% | -90.8% | 138.8% | |
| LTM Mar 2026 | $59.25M | +4936.3% | — | 74.8% | |
| LTM Mar 2026 | $56M | +49.1% | -32.5% | 1254.3% | |
| LTM Mar 2026 | $54.89M | +83065.2% | +383.8% | 554.8% | |
| LTM Mar 2026 | $30.73M | -83.5% | +646.6% | — | |
| LTM Mar 2026 | $28.03M | +3.2% | +467.3% | 189.6% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.15M | -31.8% | — | — |
| Peer median (excluding OCGN) | $59.25M | +2511.1% | +205.8% | 189.6% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| Deferred Income Tax | (52K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.96M | 10.54M | 9.22M | 7.43M | 7.71M |
| Change in Working Capital | 2.49M | 9.2M | (13.16M) | 3.67M | (523K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.5M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.01M) | 9.2M | (13.16M) | 3.67M | (523K) |
| Other Non-Cash Items | 799K | 6.51M | 4.26M | (1.15M) | 1.31M |
| Operating Cash Flow | (47.94M) | (60.08M) | (62.05M) | (42.14M) | (56.96M) |
| Capital Expenditures | (939K) | (4.46M) | (10.48M) | (3.39M) | (185K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (13.27M) | (3.95M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 17.5M | 0 | 0 |
| Other Investing Activities | (877K) | 761K | 0 | 0 | (126K) |
| Investing Cash Flow | (1.82M) | (16.97M) | 3.08M | (3.39M) | (311K) |
| Debt Repayment | (10K) | 500K | 500K | 30M | (1M) |
| Common Stock Issued | 129.21M | 59.57M | 20.8M | 38.56M | 18.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.53M) | (592K) | (68K) | (3.7M) | 0 |
| Financing Cash Flow | 120.68M | 59.48M | 20.88M | 64.86M | 17.33M |
| Effect of Forex Changes | (325) | 25K | (5K) | 28K | 13K |
| Net Change in Cash | 70.92M | (17.55M) | (38.1M) | 19.36M | (39.93M) |
| Free Cash Flow | (48.88M) | (64.54M) | (72.53M) | (45.53M) | (57.15M) |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.